Halozyme Therapeutics, Inc. (HALO) Description, Stock price, News & Info

#ThinkSabio Latest News

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer